Neurolux Inc.

Neurolux Inc., a for-profit manufacturer of advanced biomedical and neuroscience technologies based in Northfield, Illinois, develops wireless implantable physiological monitoring devices, optogenetic systems, and engineered tissue platforms for federal research agencies as a prime contractor and self-certified small disadvantaged business. The company operates exclusively as a prime (100% of awards) and does not subcontract.

Neurolux's federal footprint centers on NIH-funded research device development and a single, high-value defense prototype contract. The National Institute of Mental Health leads customer concentration by award count (8 awards, $45 thousand combined potential value), followed by the National Institute on Drug Abuse (2 awards, $18 thousand) and the National Institute of Environmental Health Sciences (2 awards, $12 thousand); however, the Department of the Army Research Development and Engineering Command anchors 99% of combined potential value with a $1.467 million Other Transaction Agreement awarded March 16, 2026, for development of a physiological status monitoring device for canine first responders, with performance through March 15, 2027, in Northfield. Representative NIH grant work includes a $999,562 Project Grant from the National Institute of Mental Health (CFDA 93.242) awarded September 24, 2025, for development and validation of the Compliant Reversible Actuator and Detector Leveraging Electrophysiology for Organoids (ORGANOID-CRADLE), extending through September 2027; a $525,824 Project Grant from the National Institute of Environmental Health Sciences (CFDA 93.113) awarded September 1, 2025, for commercialization of an Electromechanically Monitored Engineered Heart Tissue (EMEHT) platform through August 2027; and a wireless implantable mechano-acoustic recording device grant from the National Institute of Mental Health awarded September 22, 2022, with phase-II integration of closed-loop optogenetics extending through July 2027.

Neurolux's capability portfolio spans fully implantable, wireless, battery-free physiological sensors for small animal models using advanced inertial measurement unit technology and Bluetooth Low Energy 5.2 transmission; optogenetic systems integrating multi-electrode arrays and light-emitting diodes for neural recording and stimulation in organoid and tissue culture; and consumable flexible electronics for cardiac and tissue electromechanical assessment. The company manufactures analytical laboratory instruments and semiconductor-based devices (top NAICS categories) under laboratory equipment and supplies classification (primary PSC).

Activity shows concentrated peaks in 2022 (5 awards) and scattered recent work, with four awards (combined potential value $1.5 million) reaching completion inside the next twenty-four months. The Veterans Integrated Service Network 1 holds one small purchase order ($19.6 thousand, September 2022) for optogenetic instruments; the National Institute on Drug Abuse and National Institute of Mental Health placed multiple purchase orders for optogenetic systems between February and June 2022 (ceiling values $15.1 thousand and $18.05 thousand respectively).

NeuroLux system provides invasive tools with no external antennas, batteries, fiber optic cables, or head mount. The implants have ultra light weight construction (0.02 g), which allows subjects to move naturally as individuals or as interacting members of social groups.